The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
- Anti-infective drug discovery: drug target identification, characterization and validation; novel screening methods and assay development; molecular and medicinal chemical characterization of inhibitors; structure-guided drug design; preclinical studies using animal models
- Antimicrobial resistance: mechanisms and regulation of antimicrobial resistance; emergence, dissemination, and maintenance of resistance; strategies for the prevention of resistance; molecular characterization of resistant pathogens
Shared Interests and Overlaps
There are shared interests with Synthetic and Biological Chemistry A Study Section (SBCA) and Synthetic and Biological Chemistry B Study Section (SBCB) SBCB in the area of anti-infective drug development. Grant applications focused on the syntheses of small molecules or natural products with limited biological assessments may be reviewed in SBCA or SBCB. Applications involving some synthesis but more focused on the preclinical biological characterization of leads may be reviewed in DDR or IDM (82).
There are shared interests with High-Throughput Screening Special Emphasis Panel [ZRG1 BST-F (55)] in the area of anti-infective drug discovery and development. Grant applications that focus on developing novel high throughput screens for small molecule hits and immunotherapeutics may be reviewed in BST (55). R21or R03 applications that focus on identifying anti-infective targets, molecular mechanisms of action, and the development of lead compounds for anti-infective therapeutics may be reviewed in IDM (82).
There are shared interests with Bacterial Pathogenesis Study Section (BACP), HIBP, CRFS, PTHE, and VIRA & VIRB in the area of antibacterial, antiparasitic, antifungal and antiviral drug development. Grant applications focused on the pathogenesis of bacteria, eukaryotic pathogens, or viruses, using known drugs or molecular probes may be reviewed in these panels. R21 or R03 applications that focus on the treatment of these pathogens may be reviewed in IDM (82).
There are shared interests with Prokaryotic Cell and Molecular Biology Study Section (PCMB) in the area of antibacterial strategies. Grant applications that focus on molecular mechanisms of potential bacterial drug targets may be reviewed in PCMB. R21 or R03 Applications that focus on the development of antibacterial drugs may be reviewed in IDM (82).